Joseph Fogerty
About Joseph Fogerty
Joseph Fogerty is a scientist specializing in the regenerative properties of the zebrafish retina, particularly focusing on Muller glia and retinal neuron regeneration. He has worked at Abeona Therapeutics since 2021 and has extensive experience in research and laboratory management.
Work at Abeona Therapeutics
Joseph Fogerty has been employed as a Scientist at Abeona Therapeutics since 2021. His work focuses on advancing research in regenerative medicine, particularly in relation to retinal health. Based in Cleveland, Ohio, he contributes to the company's initiatives aimed at developing innovative therapies for ocular diseases. His expertise in retinal neuron regeneration aligns with Abeona's mission to address unmet medical needs in the field of gene and cell therapy.
Education and Expertise
Joseph Fogerty holds a Doctor of Philosophy (PhD) in Cell Biology, Neurobiology, and Anatomy from the Medical College of Wisconsin, where he studied from 2007 to 2013. Prior to this, he earned a Bachelor of Science (BS) in Biology from Carroll University, completing his studies in 2000. His educational background provides a strong foundation for his research in retinal regeneration and cellular mechanisms.
Background
Joseph Fogerty has a diverse professional background in scientific research. He served as a Laboratory Manager at the Medical College of Wisconsin from 2000 to 2007, overseeing laboratory operations. Following this role, he worked as a Postdoctoral Fellow at the Cleveland Clinic from 2013 to 2021, where he focused on retinal research. His career spans over two decades in various capacities within the field of biomedical research.
Research Focus and Techniques
Fogerty's research primarily investigates the regenerative properties of the zebrafish retina, with a particular emphasis on the role of Muller glia in retinal neuron regeneration. He has utilized advanced techniques such as CRISPR and TALEN to generate mutations in microRNAs that are critical for photoreceptor function. His work also explores signaling mechanisms that may inform treatment strategies for human retinal diseases and interventions to promote Muller cell activation for photoreceptor replacement.